Chairman & Managing Director
Marc Wayne, Chairman of the Board, Managing Director, Beckley Canopy | Serial entrepreneur and noted pioneer in the Canadian medical cannabis sector, Marc co-founded Bedrocan Canada in 2012, one of the first federally licensed producers of medical marijuana, and took the company public in 2014. In 2015, Marc successfully sold Bedrocan to Tweed Marijuana Inc., a key transaction that lead to the formation of Canopy Growth Corporation, which is now the largest medical cannabis producer in the world. Marc acted as Managing Director of Canopy Growth until December 2016, and now serves as Founding President of Canopy Health Innovations. Marc was also the founding Chair of the Cannabis Canada Association and instrumental in developing the Canadian Consortium for the Investigation of Cannabinoids (CCIC) – a global innovator in education and research on medical cannabis.
Chair of Scientific Advisory Board
World-renowned pioneer in drug policy reform and scientific research into psychoactive substances. As founder of the Beckley Foundation, Amanda has advised governments and the UN, partnered with renowned academic institutions (such as Imperial College, UCL, and Johns Hopkins), and co-authored over 40 peer-reviewed scientific publications – many with groundbreaking results. Notable achievements include the Global Cannabis Commission in 2008 – a turning point in the UN’s attitude to cannabis reform; the first ever brain imaging study on LSD with Imperial College; and the UK’s first study into the effects of CBD and its interactions with THC with King’s College London in 2008.
A close collaborator of the Beckley Foundation for almost a decade, in 2016 he co-founded Beckley Research & Innovations to develop a for-profit arm of Beckley’s work with a strong focus on medical cannabis. Involved in the formation of the Beckley-Exeter Cannabis Research Program in partnership with Exeter University, Cosmo has led the R&D efforts for a proprietary cannabinoid formulation which is currently being tested in Beckley-Canopy’s first human trial looking at the effects of non-psychoactive cannabinoids and terpenes in the treatment of a major disease area.
25 years of experience founding, managing, and advising growth companies, including strategy, corporate finance, capital markets, corporate development, M&A, financial reporting, and governance. Chris’ functional experience across executive positions spans Treasurer, Executive Vice President, Chief Financial Officer, President, and Chief Executive Officer. His broad industry experience includes technology, communications, agriculture, food processing, financial services, healthcare, and sustainability. Chris has 25 years of public company Board experience and currently sits on the Board of Canopy Growth Corporation and Canopy Health Innovations.
Chief Financial Officer
Over 20 years of experience as CFO in both private and publicly quoted Medical Technology and Life Science companies, covering drug development, animal health, medical devices and diagnostics. Specialising in start-up and early stage businesses, Michael has led over 50 equity fundraisings and been involved in numerous mergers, acquisitions and exits in UK, EU, USA and South Africa.
Head of Clinical Development
Innovative clinical development professional with over 15 years’ experience developing pharmaceuticals and natural medicines from pre-clinical through to commercialisation. Tim has led research teams globally in a wide range of indications and sectors. Prior to joining Beckley Canopy Therapeutics as the Head of Clinical Development, Tim has worked in CROs, startup biotech companies such as Shield Therapeutics, and Big Pharma organisations, such as GSK and Allergan.
Director of Clinical Operations
Over 15 years of experience in clinical development gained through the management of approximately 50 trials, across 15 therapeutic areas in all phases and geographical regions within numerous pharmaceutical and biotechnology organisations. Experienced in expanded access programs, inspection management, department process improvement as well as vendor oversight. Kalpana has successfully led cross functional global teams to deliver critical data at key drug life cycle stages, whilst also developing innovative solutions when faced with patient recruitment, budgetary, and resource obstacles.
Highly respected and internationally renowned pain specialist and medical cannabis researcher. Chief Medical Officer, Canopy Growth and Director of Clinical Research at the Alan Edwards Pain Management Unit of McGill University. Executive Director of non-profit Canadian Consortium for the Investigation of Cannabinoids (CCIC). Served as vice-chair of the task force providing guidance to the Canadian government as it prepares to introduce legislation to legalize cannabis.
Accomplished expert in the development and commercialization of innovative biopharmaceutical products and technologies with more than 15 years’ experience in product development, opportunity evaluation, business development, and strategic marketing in life sciences. Before joining Canopy Health Innovations as Chief Operating Officer, Dr. Batal led business development at Purdue Pharma Canada in a VP role, and the life sciences practice of SHIFT Health serving global big pharma mandates.
Head of Intellectual Property
Expert in all aspects of intellectual property as co-founder of IP Checkups and formerly Vice President, Intellectual Property for Gilead Sciences Inc, one of the leading biopharmaceutical firms in the world, where he was responsible for intellectual property and competitive intelligence services. IP Checkups are working exclusively on cannabis with the Canopy group.